


## VEGFR-2/DHFR-IN-1

<b>Cat. No.:</b>	HY-151458
<b>CAS No.:</b>	2831498-15-6
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>18</sub> ClNO <sub>4</sub>
<b>Molecular Weight:</b>	371.81
<b>Target:</b>	Bacterial; VEGFR; Dihydrofolate reductase (DHFR); Fungal
<b>Pathway:</b>	Anti-infection; Protein Tyrosine Kinase/RTK; Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	VEGFR-2/DHFR-IN-1 (compound 8b) is an inhibitor of VEGFR-2 and DHFR with IC <sub>50</sub> s of 0.384 and 7.881 μM, respectively. VEGFR-2/DHFR-IN-1 shows good antibacterial activities against Escherichia coli, Streptococcus faecalis, Salmonella enterica, MSSA and MRSA with MIC values of 16, 16, 16, 8, and 16 μg/mL, respectively. VEGFR-2/DHFR-IN-1 exhibits good cytotoxic activities against C26, HepG2, and MCF7 cancer cell lines with IC <sub>50</sub> values of 2.97-7.12 μM. VEGFR-2/DHFR-IN-1 can be used for the research of cancer <sup>[1]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	VEGFR-2 0.384 μM (IC <sub>50</sub> )	DHFR 7.881 μM (IC <sub>50</sub> )								
<b>In Vitro</b>	<p>VEGFR-2/DHFR-IN-1 (2-1024 μg/mL; 18-72 h) shows antibacterial and antifungal activities with MIC values of 16, 64, 16, 16, 8, 16, 64 and 256 μg/mL for Escherichia coli, Pseudomonas aeruginosa, Streptococcus faecalis, Salmonella enterica, MSSA, MRSA, Candida albicans and Aspergillus niger, respectively<sup>[1]</sup>.</p> <p>VEGFR-2/DHFR-IN-1 (0.5-100 μM; 48 h) exhibits anticancer activities<sup>[1]</sup>.</p> <p>VEGFR-2/DHFR-IN-1 (0-100 μM; 30 min) shows DHFR and VEGFR-2 inhibitory activities with IC<sub>50</sub>s of 7.881 and 0.384 μM, respectively<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>C26, HepG2, MCF7 and H69PR cell lines</td> </tr> <tr> <td>Concentration:</td> <td>0.5, 1, 5, 10, 25, 50, 80 and 100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Showed anticancer activities to C26, HepG2, MCF7 and H69PR cells with IC<sub>50</sub>s of 2.97, 7.12, 3.58 and 12.79 μM, respectively.</td> </tr> </table>		Cell Line:	C26, HepG2, MCF7 and H69PR cell lines	Concentration:	0.5, 1, 5, 10, 25, 50, 80 and 100 μM	Incubation Time:	48 hours	Result:	Showed anticancer activities to C26, HepG2, MCF7 and H69PR cells with IC <sub>50</sub> s of 2.97, 7.12, 3.58 and 12.79 μM, respectively.
Cell Line:	C26, HepG2, MCF7 and H69PR cell lines									
Concentration:	0.5, 1, 5, 10, 25, 50, 80 and 100 μM									
Incubation Time:	48 hours									
Result:	Showed anticancer activities to C26, HepG2, MCF7 and H69PR cells with IC <sub>50</sub> s of 2.97, 7.12, 3.58 and 12.79 μM, respectively.									

### REFERENCES

[1]. Pham EC, et al. Design, Microwave-Assisted Synthesis, Antimicrobial and Anticancer Evaluation, and In Silico Studies of Some 2-Naphthamide Derivatives as DHFR and VEGFR-2 Inhibitors. ACS. 2022.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA